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Abstract: With the current widespread use of dolutegravir in low-income countries, the understanding
of the impact of nucleoside reverse transcriptase inhibitor (NRTI-) associated mutations on
the efficacy of dolutegravir-containing antiretroviral therapy (ART) is of utmost importance.
We describe a rare case of a patient with pre-existing M184V/I mutation and virological failure
on a dolutegravir/lamivudine/abacavir regimen with the emergence of integrase strand transfer
inhibitor resistance mutations. Additional risk factors, which may have triggered the virological
failure, included suboptimal adherence and low nadir CD4+ cell count. This case illustrates that
dolutegravir-containing triple-therapy should be prescribed with caution to patients with pre-existing
M184V/I mutation and poor efficacy of the reverse transcriptase inhibitor backbone. In addition, this
case highlights the need for viral load monitoring in patients on dolutegravir-containing regimens in
settings with a high prevalence of the M184V/I mutation such as in low-income countries.
Keywords: HIV-1; antiretroviral therapy; dolutegravir; virological failure; drug resistance; M184V/I
mutation; integrase strand transfer inhibitor
1. Introduction
Infection with the human immunodeficiency virus type 1 (HIV-1) can be very efficiently treated
with combination antiretroviral therapy (cART), however, this success can be jeopardized by the
emergence of HIV-1 drug resistance. Dolutegravir (DTG) is a second-generation integrase strand
transfer inhibitor (INSTI) often used as a component of preferred cART due to its favorable properties,
including a high genetic barrier to resistance, good tolerability and safety profile, and low potential for
drug-drug interactions [1]. In clinical trials at 96 and 148 weeks, no emergence of resistance to INSTI
has been reported among patients failing on first-line DTG-containing triple-therapy. However, real-life
data from treatment-naïve and treatment-experienced patients on DTG-containing triple-therapy
describe a few cases of virologic failure with the emergence of HIV-1 resistance to INSTIs [2–6].
With the current widespread use of DTG in low-income countries, the understanding of the
impact of nucleoside reverse transcriptase inhibitor (NRTI-) associated mutations on the efficacy of
dolutegravir-containing ART is of utmost importance [7]. The M184V/I mutation is one of the most
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common NRTI-associated mutations in HIV-1 infected patients and typically selected in patients
failing on lamivudine (3TC) or emtricitabine (FTC) containing regimen. The presence of M184V/I
reduces the susceptibility to these drugs by more than 100-fold and additionally causes an impaired
efficacy to abacavir (ABC). In contrast, it enhances the susceptibility to tenofovir disoproxil fumarate
(TDF) and tenofovir alafenamide fumarate (TAF). Recently, a prospective study using data from five
large HIV cohorts in four European countries assessed the efficacy of the ABC/3TC/DTG regimen
in virologically suppressed, treatment-experienced patients and found no evidence for an impact of
previously acquired M184V/I mutation on the incidence of virological failure [8]. Furthermore, no new
mutations were observed in reverse transcriptase or integrase after virological failure in any of the
patients in whom genotyping was successfully performed. However, due to the short observation time
and the low number of virological failure events, the study concluded that additional analyses are
required to demonstrate whether these findings remain robust during an extended observation period.
Here we describe a rare case of a patient with a pre-existing M184V/I mutation who failed on the
ABC/3TC/DTG regimen with the emergence of resistance to all currently licensed INSTIs including the
second-generation INSTIs DTG and bictegravir (BIC).
2. Case Description and Results
A 45-year-old man who has sex with men was diagnosed with HIV-1 infection in March 1997.
The CD4+ cell count at the time of diagnosis revealed 325 cells per microliter (µL) blood with an
HIV-1 viral load of 94,267 copies (cp) per milliliter (mL) plasma. His medical history was remarkable
for chronic depression and intermittent illicit drug use. ART consisting of nelfinavir (NFV), 3TC,
and stavudine (d4T) was initiated and virus suppression below the limit of quantification of 50 cp/mL
plasma was achieved six months later (Figure 1). According to the autovaccination hypothesis that
re-exposure to HIV-1 during treatment interruptions may stimulate the HIV-1 specific immune response
and lead to low viremia after the withdrawal of ART, the patients were enrolled into the Swiss-Spanish
Intermittent Treatment Trial (SSITT) in October 1999 [9]. In brief, in this trial ART was interrupted
for 2 weeks, restarted, and continued for 8 weeks. After four such cycles, treatment was indefinitely
suspended. During the indefinite treatment interruption period, the viral load increased to a maximum
of 25,558 cp/mL and decreased to a minimum of zero copies/mL as measured with a single copy
assay when treatment with NFV, 3TC, and d4T was re-initiated. Longitudinal blood samples were
analyzed using an in-house allele-specific-PCR (AS-PCR) to determine the frequency of M184V and
L90M drug-resistant variants [10]. The M184V mutation was not detectable in the second structured
treatment interruption cycle. In the fifth cycle, six time-points were measured, and one of them was
positive for the M184V mutation at a low frequency of 0.9% (Figure 1). The amplification of samples at
the other short structured treatment interruption cycles and additional time points during the fifth
cycle was unsuccessful.
Following the SSITT trial, the patient remained off ART until October 2008. At that time, the CD4+
cell count had decreased to a nadir of 167 cells/µL blood with a viral load of 114,000 cp/mL plasma
and the patient had developed candida esophagitis. Prior to developing symptoms, he did not want
to reinitiate treatment although this was recommended according to treatment guidelines at that
time [11]. In October 2007, a genotypic HIV resistance test using Sanger technology was performed
from a blood repository sample taken before the patient started his first ART in 1997. This resistance
test revealed infection with HIV-1 subtype B and the presence of the accessory mutations M36I, I62V,
and V77I not causing any clinically relevant resistance to antiretroviral drugs. The M184V mutation,
which was identified during the SSITT trial, was not present in 1997, suggesting a selection of the
M184V mutation during the structured treatment interruption cycles (Figure 1). In October 2008,
ART with ritonavir (RTV) boosted lopinavir (LPV) and tenofovir disoproxil fumarate (TDF)/FTC was
started. However, the treatment was switched to ritonavir-boosted fosamprenavir (FAPV) with the
continuation of TDF/FTC some days later because of severe LPV/RTV-associated diarrhea. With this
ART the viral load remained <50 copies/mL plasma. In May 2011, the patient experienced virological
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failure with an increased viral load of 3390 copies/mL plasma, most likely caused by suboptimal
adherence as self-reported by the patient. The genotypic resistance test using Sanger technology
revealed the M184I mutation causing high- and low-level resistance to 3TC/FTC and ABC, respectively.
In addition, the accessory protease mutations K20R, L10I, I13V, and G16E were detected. ART was
switched to RTV-boosted darunavir (DRV) and raltegravir (RGV) with the continuation of TDF/FTC.
With this salvage therapy, the viral load was fully suppressed one month later and ART was continued
with DRV/TDF/FTC. Within the following 4 years, the viral load remained always below the limit of
quantification of <20 cp/mL plasma, but viral RNA was detectable at most time points. In June 2015,
the patient demanded to switch to a single-tablet regimen (STR), because of the pill burden of his ART.
Hence, ART was switched to the STR DTG/3TC/ABC. Afterward, intermittent low-level viremia up to
383 cp/mL occurred, most likely associated with periods of poor ART adherence. Indeed, the patient
reported to miss his ART regularly for several consecutive days, often related to concomitant illicit drug
use. During periods of good adherence, however, the viral load decreased to levels <20 cp/mL plasma.
In October 2019, when the viral load increased from 45 cp/mL to 183 cp/mL plasma, a genotypic
resistance test was performed. This resistance test newly revealed the E138K, Q148R, and R263K INSTI
mutations at frequencies of 100% by means of next-generation sequencing (NGS), causing high-level
resistance to RAL, EVG, DTG, and BIC. In addition, the prior M184V mutation—but no other NRTI
mutations—was detected at a frequency of 100%. The patient’s ART was switched to a salvage regimen
consisting of twice-daily RTV-boosted DRV, twice-daily etravirine (ETR), and tenofovir alafenamide
fumarate (TAF)/FTC (Figure 1). With this salvage regimen, the viral load returned to levels <20 cp/mL
plasma and remained suppressed until present in January 2020.
Figure 1. Virological evolution and emergence of resistance-associated mutations (arrows pointing
downwards) of our patient since initiation of antiretroviral treatment. Abbreviations: ART:
antiretroviral treatment, 3TC: lamivudine, D4T: stavudine, NFV: nelfinavir, SSITT: Swiss Spanish
Intermittent Treatment Trial, FAPV/r: fosamprenavir/ritonavir, TDF: tenofovir disoproxil-fumarate,
FTC: emtricitabine, (*) add-on raltegravir for one month, DRV/r: darunavir/ritonavir, ETV: etravirine,
TAF: tenofovir alafenamide, LOQ: level of quantification. The persisting M184V/I mutation is highlighted
in bold.
3. Discussion
This is a rare case of a patient with pre-existing M184V/I mutation and virological failure on a
DTG/3TC/ABC regimen with the emergence of INSTI resistance mutations. Most likely, the virological
failure was triggered by suboptimal adherence and a low nadir CD4+ cell count.
Virological failure with the emergence of resistance to INSTIs on a DTG-based triple-therapy is a
rare event with only a few cases published so far [2–6]. Our patient exhibited several features that
might have increased his risk for a virological failure: Firstly, the patient re-started his ART following a
structured treatment interruption with a low CD4+ cell count of 167 cells/µl blood. Indeed, a CD4+ cell
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count below 200 cells/µL blood is associated with less favorable virological, immunological, and clinical
outcomes in many studies [12]. Secondly, the patient reported suboptimal adherence during several
years with detectable low-level viremia and viral blips. Thirdly, the patient harbored the M184V/I
mutation, which causes reduced susceptibility to two (3TC, ABC) out of the three components of the
DTG/3TC/ABC regimen. A recent European observational study assessed the impact of the M184V/I
mutation on the virological failure rate on the DTG/3TC/ABC regimen [8]. Of the 1626 patients included,
137 (8.4%) harbored the genotypically documented M184V/I mutation. Patients with the M184V/I
mutation had a lower CD4 nadir and a long history of antiviral treatment. Overall, the study observed a
very low virological failure rate (1.3%) after the switch to ABC/3TC/DTG, with no statistically significant
difference in the virological failure incidence among patients with or without M184V/I. However,
the generalization of the results is limited due to the small sample size and the short observational
period (median follow-up 288 days). Furthermore, an indication bias may have occurred as physicians
tended to prescribe a single-pill regimen in patients with documented resistance mutations only if
they were confident about patients’ adherence [8]. It is convincing that in our case the combination
of poor adherence with low-level replication and pre-existing M184V/I mutation, first observed as a
low-abundant variant in the SSITT study, led to virological failure and consecutively emergence of
INSTI resistance.
The learning points of this case are manifold: Firstly, this case illustrates that patients with a
low CD4+ cell count nadir, pre-existing NRTI-associated mutations, and poor adherence are not
candidates for a DTG-containing regimen with limited efficacy of the NRTI-backbone, at least not
without close monitoring of the viral load. Other INSTIs with a lower resistance barrier than DTG,
such as elvitegravir (EVG) in the co-formulation EVG/cobicistat/FTC/TAF, showed to be effective
in maintaining viral suppression despite archived M184V/I mutations at week 24 in a prospective
open-label study. However, in this study-population the median nadir CD4+ cell count was high
(724 cells/µL blood), the sample size was small, and the observational period was rather short [13].
Furthermore, TAF exhibits still full efficacy in the presence of the M184V/I mutation in contrast to
ABC. Secondly, our case and others indicate that DTG might have a lower resistance barrier than
previously postulated, in particular when given with a not fully active backbone. This finding may
have important consequences in light of the current widespread use of DTG in low-income countries.
In this setting, pre-existing NRTI-associated mutations—including the M184V/I mutation—are highly
prevalent and there is no possibility of close viral load monitoring. In addition, the cut-off of a viral
load >1000 cp/mL plasma recommended by the World Health Organization (WHO) for the definition
of virological failure will lead to delayed action when a patient fails on a DTG-containing regimen with
an increased risk for the emergence of resistance to INSTIs and the loss of future treatment options [7].
Given that TDF/TAF still exhibits full efficacy in the presence of the M184V/I mutation, this backbone
component should be preferred in combination with DTG in low—and middle-income countries.
Our case has several limitations. Firstly, DTG drug levels were not measured at the time of
virological failure and therefore suboptimal adherence as an important co-factor for the virological
failure cannot be proven. However, self-reported adherence of missed doses of ART—as systematically
collected in these patients within the Swiss HIV Cohort Study—is a good predictor for poor adherence
and associated with an increased risk of both viral failure and death [14]. Hence, monitoring adherence
helps to identify patients at risk for negative clinical outcomes and offers opportunities for intervention.
Another limitation is that we didn’t sequence the integrase gene at baseline when the patient started his
first cART, thus, we cannot rule out pre-existing INSTI-associated mutations. However, a recent large
study within the SHCS clearly indicated that resistance-associated mutations to INSTIs were almost
absent in Switzerland in drug naïve patients [15]. Finally, we were unable to perform next-generation
sequencing of the virus from different time points because there was no plasma left for extraction.
Therefore, we cannot exclude that the M184I mutation detected at different time points may potentially
be linked to different viral quasispecies. However, while this discrimination is interesting from a viral
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evolution point of view, such information most likely would not have had any impact on the clinical
management of the patient.
4. Conclusions
In conclusion, we describe a rare case of a virological failure on the DTG/3TC/ABC regimen with
the emergence of resistance to all INSTIs in a patient with pre-existing M184V/I mutation. Other risk
factors, which may have triggered the virological failure, included suboptimal adherence and a low
nadir CD4+ cell count. This case illustrates that DTG/3TC/ABC should be prescribed with caution to
patients with pre-existing M184V/I mutation, a low CD4 cell count, and/or poor adherence. Even more
caution in this patient population is probably indicated when DTG/3TC containing dual regimens
are planned. In addition, this case questions the current understanding of DTG as a drug with high
resistance barrier similar to contemporary boosted PIs and highlights the need for close viral load
monitoring in countries with a high prevalence of NRTI-mutations.
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